Velsera Enhances Illumina's Comprehensive Test for Cancer with New Approval in Japan

Velsera Enhances Illumina's Comprehensive Testing Framework in Japan

On May 30, 2025, Velsera announced a significant milestone as its clinical Knowledgebase is now integrated into Illumina's TruSight™ Oncology Comprehensive (TSO Comp) test, which has received regulatory approval from Japan's Ministry of Health, Labour and Welfare. This approval marks a pivotal development for personalized medicine and oncology in Japan, making advanced genomic profiling accessible for cancer patients.

The TSO Comp test is renowned for its next-generation sequencing (NGS) capabilities, allowing for comprehensive genomic profiling of solid tumors. This advanced assay detects various genomic alterations, including single nucleotide variants, indels (insertions and deletions), copy number changes, and gene fusions. Remarkably, it can perform these analyses from a single tumor sample, significantly simplifying the diagnostic process for clinicians.

Integrating Velsera's Knowledgebase into the TSO Comp framework enhances the test's utility by linking identified genetic variants to curated clinical evidence, actionable treatment guidelines, and relevant research. This ensures that every report generated reflects the latest scientific findings and regulatory guidelines, thereby equipping healthcare providers with critical information they need to make informed treatment decisions.

The Japanese government's initiative to broaden access to standardized, evidence-based precision oncology is further supported by this development. With the TSO Comp test now commercially available in Japan, clinicians can leverage actionable data to tailor treatment strategies more effectively, ultimately improving clinical outcomes for cancer patients.

Velsera is committed to bridging the gap between healthcare services and clinical decision-making through its data-driven approach. By accelerating the delivery of genomic insights into clinical settings, the company significantly contributes to the advancement of precision medicine. This philosophy underpins Velsera’s operations and informs its mission to ensure every patient receives the right therapy at the right time.

This breakthrough will also be highlighted at the American Society of Clinical Oncology (ASCO) Annual Meeting to be held from May 31 to June 2, 2025, where Velsera's clinical portfolio will take center stage, demonstrating its leadership role in the intersection of healthcare and technology.

Founded in 2023 through the merger of Seven Bridges, PierianDx, and UgenTec, Velsera operates globally, spanning markets in the U.S., Europe, and Asia. Its mission focuses on the development of innovative tools that support precision medicine, helping clinicians and researchers make better decisions regarding patient care.

As the healthcare landscape continues to evolve, Velsera's contributions epitomize the ongoing shift toward data-centric and patient-focused treatment paradigms. For more information on their pioneering solutions, visit Velsera’s official website.